{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:48:50Z","timestamp":1783385330191,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12328-022-01590-z","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T09:03:04Z","timestamp":1645693384000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-5766","authenticated-orcid":false,"given":"Seita","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihisa","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Miyagawa-Hayashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"1590_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257\u201365.","journal-title":"Lancet Oncol"},{"key":"1590_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","volume":"17","author":"D Cella","year":"2016","unstructured":"Cella D, Gr\u00fcnwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:994\u20131003.","journal-title":"Lancet Oncol"},{"key":"1590_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New Engl J Medicine. 2016;375:1856\u201367.","journal-title":"New Engl J Medicine"},{"key":"1590_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. New Engl J Medicine. 2015;372:311\u20139.","journal-title":"New Engl J Medicine"},{"key":"1590_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1590_CR7","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol"},{"key":"1590_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. New Engl J Medicine. 2012;366:2443\u201354.","journal-title":"New Engl J Medicine"},{"key":"1590_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"1590_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865\u201371.","journal-title":"JAMA Oncol"},{"key":"1590_CR11","doi-asserted-by":"publisher","first-page":"e001622","DOI":"10.1136\/jitc-2020-001622","volume":"8","author":"M Allouchery","year":"2020","unstructured":"Allouchery M, Lombard T, Martin M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8:e001622.","journal-title":"J Immunother Cancer"},{"key":"1590_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drug. 2017;35:529\u201336.","journal-title":"Invest New Drug"},{"key":"1590_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"key":"1590_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, Ishizu Y, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol. 2020;55:653\u201361.","journal-title":"J Gastroenterol"},{"key":"1590_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroentero. 2020;26:353\u201365.","journal-title":"World J Gastroentero"},{"key":"1590_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","volume":"36","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drug. 2018;36:144\u20136.","journal-title":"Invest New Drug"},{"key":"1590_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/his.14000","volume":"76","author":"Y Zen","year":"2020","unstructured":"Zen Y, Chen Y, Jeng Y, et al. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology. 2020;76:470\u201380.","journal-title":"Histopathology"},{"key":"1590_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/imt-2019-0077","volume":"11","author":"A C\u01celug\u01cereanu","year":"2019","unstructured":"C\u01celug\u01cereanu A, Rompteaux P, Bohelay G, et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy. 2019;11:1005\u201313.","journal-title":"Immunotherapy"},{"key":"1590_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000496933","volume":"12","author":"H Oda","year":"2019","unstructured":"Oda H, Ishihara M, Miyahara Y, et al. First case of cytokine release syndrome after nivolumab for gastric cancer. Case Rep Oncol. 2019;12:147\u201356.","journal-title":"Case Rep Oncol"},{"key":"1590_CR20","doi-asserted-by":"publisher","first-page":"e000487","DOI":"10.1136\/bmjgast-2020-000487","volume":"7","author":"T McClure","year":"2020","unstructured":"McClure T, Cui W, Asadi K, et al. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. BMJ Open Gastroenterol. 2020;7:e000487.","journal-title":"BMJ Open Gastroenterol"},{"key":"1590_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Yamamoto T, et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int. 2021;15:1278\u201387.","journal-title":"Hepatol Int"},{"key":"1590_CR22","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. Esmo Open. 2017;2:e000268.","journal-title":"Esmo Open"},{"key":"1590_CR23","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jgh.14136","volume":"33","author":"C Hamoir","year":"2018","unstructured":"Hamoir C, Vos M, Clinckart F, et al. Hepatobiliary and pancreatic: nivolumab-related cholangiopathy. J Gastroen Hepatol. 2018;33:1695.","journal-title":"J Gastroen Hepatol"},{"key":"1590_CR24","doi-asserted-by":"publisher","first-page":"E259","DOI":"10.1055\/a-0640-2392","volume":"50","author":"N Kuraoka","year":"2018","unstructured":"Kuraoka N, Hara K, Terai S, et al. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy. 2018;50:E259\u201361.","journal-title":"Endoscopy"},{"key":"1590_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","volume":"58","author":"M Kono","year":"2019","unstructured":"Kono M, Sakurai T, Okamoto K, et al. Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. Internal Med. 2019;58:1263\u20136.","journal-title":"Internal Med"},{"key":"1590_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.11.021","volume":"107","author":"S Noda-Narita","year":"2019","unstructured":"Noda-Narita S, Mizuno S, Noguchi S, et al. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. Eur J Cancer. 2019;107:93\u20136.","journal-title":"Eur J Cancer"},{"key":"1590_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2169\/internalmedicine.2330-18","volume":"58","author":"K Sawada","year":"2019","unstructured":"Sawada K, Shonaka T, Nishikawa Y, et al. Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature. Intern Med. 2019;58:1747\u201352.","journal-title":"Intern Med"},{"key":"1590_CR28","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jtho.2018.09.016","volume":"14","author":"EL Tallec","year":"2019","unstructured":"Tallec EL, Ricordel C, Triquet L, et al. An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab. J Thorac Oncol. 2019;14:e13\u20135.","journal-title":"J Thorac Oncol"},{"key":"1590_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.022","volume":"115","author":"M Fouchard","year":"2019","unstructured":"Fouchard M, Jantzem H, Quere G, et al. Three cases of immune cholangitis related to anti\u2013programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. Eur J Cancer. 2019;115:107\u201310.","journal-title":"Eur J Cancer"},{"key":"1590_CR30","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.jtho.2019.04.023","volume":"14","author":"B Anderson","year":"2019","unstructured":"Anderson B, Dawe DE. Nivolumab-induced secondary sclerosing cholangitis with deterioration despite immunosuppression. J Thorac Oncol. 2019;14:e205\u20136.","journal-title":"J Thorac Oncol"},{"key":"1590_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12328-020-01287-1","volume":"14","author":"Y Yoshikawa","year":"2021","unstructured":"Yoshikawa Y, Imamura M, Yamaoka K, et al. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clin J Gastroenterol. 2021;14:283\u20137.","journal-title":"Clin J Gastroenterol"},{"key":"1590_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01590-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:43:22Z","timestamp":1659098602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01590-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01590-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}